VERICEL CORPORATION Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount
VERICEL CORPORATION (VCEL) reported Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate · last filed 2026-02-26
- VERICEL CORPORATION effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- VERICEL CORPORATION effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2024 was $1.09M.
- VERICEL CORPORATION effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2023 was -$704.00K, a 222.65% decline from fiscal 2022.
- VERICEL CORPORATION effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2022 was $574.00K, a 1121.28% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |
| 2024-12-31 | $1.09M 10-K · filed 2026-02-26 | |
| 2023-12-31 | -$704.00K 10-K · filed 2026-02-26 | |
| 2022-12-31 | $574.00K 10-K · filed 2025-02-27 | |
| 2021-12-31 | $47.00K 10-K · filed 2024-02-29 | |
| 2020-12-31 | $249.00K 10-K · filed 2023-02-23 | |
| 2019-12-31 | -$164.00K 10-K · filed 2022-02-24 | |
| 2018-12-31 | $839.00K 10-K · filed 2021-02-24 | |
| 2017-12-31 | $11.75M 10-K · filed 2020-02-25 | |
| 2016-12-31 | -$614.00K 10-K · filed 2019-02-26 | $614.00K 10-K · filed 2017-03-13 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-05 | |
| 2014-12-31 | $0.00 10-K · filed 2017-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |